Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2009-09-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atherosclerosis in Rheumatoid Arthritis
NCT00037336
Comprehensive Assessment of Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis
NCT03813017
Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study
NCT03776682
Lipids, Inflammation, and CV Risk in RA
NCT02714881
Study of Some Risk Factors for Developing RA
NCT03624179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rheumatoid arthritis subjects
60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort
No interventions assigned to this group
healthy controls
20 matched controls without rheumatoid arthritis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-80
* Enrolled in UCSF RA cohort already
Exclusion Criteria
* Pregnant or Lactating
* Renal failure (Creatinine \> 2mg/dL or on dialysis)
* History of MI or CAD
* History of ischemic CVA
* Symptomatic PVD
* Current uncontrolled hypertension (blood pressure \> 160/100mmHg)
* Daily prednisone \> 10mg daily
* Current smoker
* New BP med within 3 months
* New statin within 3 months
* Change in RA meds: new or increase in prednisone within 1 month, new TNF inhibitor within 2 months, titration of methotrexate, leflunomide or sulfasalazine within 3 months.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Priscilla Hsue
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Priscilla Y Hsue, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Peter Ganz, MD
Role: STUDY_DIRECTOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSF San Francisco General Hospital Vascular Research Center
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SFGH GCRC 6128
Identifier Type: -
Identifier Source: secondary_id
H11397-34652-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.